Baxter International is a healthcare company that focuses on developing and providing a wide range of medical products and services to enhance patient care. The company specializes in creating innovative therapies and solutions for various health conditions, including renal and hospital care. With a strong emphasis on sustainability and improving patient outcomes, Baxter manufactures essential medical devices, pharmaceuticals, and biotechnology products that support the treatment of chronic diseases and acute medical conditions. Their commitment to research and development drives advancements in healthcare technology, helping to meet the needs of healthcare professionals and patients worldwide. Read More
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) for violations of the federal securities laws on behalf of investors who purchased or acquired Baxter securities between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX).
NEW YORK - November 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. (NYSE: BAX) of a class action securities lawsuit.
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) between February 23, 2022 and July 30, 2025, inclusive.
Baxter’s third quarter results were met with a negative market reaction, as the company delivered top-line growth but missed Wall Street’s revenue expectations. Management attributed performance shortfalls primarily to ongoing challenges in its Infusion Therapies & Technologies division, which faced a continued pause on Novum IQ Large Volume pump shipments, and to softness in U.S. demand for IV solutions. CEO Andrew Hider candidly stated, “We are not satisfied with our current performance,” emphasizing that operational and segment-specific headwinds required immediate attention. The Healthcare Systems & Technologies segment, however, demonstrated improved performance during the quarter.
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks.
But their headline prices don’t guarantee quality, and investors should exercise caution as some have shaky business models.
NEW YORK - November 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. (NYSE: BAX) of a class action securities lawsuit.
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Baxter International, Inc. (NYSE:BAX), Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ), and Molina Healthcare, Inc. (NYSE: MOH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK - November 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. (NYSE: BAX) of a class action securities lawsuit.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $10,000 In Baxter To Contact Him Directly To Discuss Their Options
LOS ANGELES, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) for violations of the federal securities laws on behalf of investors who purchased or acquired Baxter securities between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Shares of healthcare company Baxter International (NYSE:BAX)
fell 2.9% in the afternoon session after the stock continued to fall as the company reported mixed third-quarter results, lowered its full-year guidance, and announced a plan to reduce its dividend. While adjusted earnings per share of $0.69 beat expectations, revenue of $2.84 billion fell short of forecasts. The positive earnings were overshadowed by several concerns. The company's gross margin plunged due to product mix shifts and higher manufacturing costs. Baxter also lowered its 2025 adjusted earnings outlook to a range of $2.35 to $2.40 and trimmed its full-year sales growth target. Adding to the issues, the company faced ongoing operational problems, including a shipment hold for its Novum IQ Large Volume Pump. Finally, Baxter said it would slash its quarterly dividend starting in January 2026 to free up cash to pay down debt.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.
LOS ANGELES, Oct. 31, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Baxter International Inc. (“Baxter” or “the Company”) (NYSE: BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.
NEW YORK - October 31, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Baxter International, Inc. (NYSE: BAX) of a class action securities lawsuit.
NEW YORK, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Baxter International, Inc. (NYSE:BAX), Spirit Aviation Holdings, Inc. (OTCMKTS:FLYYQ), and Molina Healthcare, Inc. (NYSE: MOH). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
